Atazanavir (Week 24 switch) — Competitive Intelligence Brief

Atazanavir (Week 24 switch) (Atazanavir (Week 24 switch)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

phase 3 HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

Atazanavir (Week 24 switch) (Atazanavir (Week 24 switch)) — Bristol-Myers Squibb. Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atazanavir (Week 24 switch) TARGET	Atazanavir (Week 24 switch)	Bristol-Myers Squibb	phase 3	HIV protease inhibitor	HIV protease
Lopinavir/r	Lopinavir/r	Universidade Federal do Rio de Janeiro	marketed	Protease inhibitor	HIV protease
Darunavir / Ritonavir + Tenofovir / Emtricitabine	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Highly active antiretroviral therapy	Highly active antiretroviral therapy	PETHEMA Foundation	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)
Darunavir/Ritonavir (Prezista)	Darunavir/Ritonavir (Prezista)	Kowa Research Institute, Inc.	marketed	HIV protease inhibitor	HIV protease
Atazanavir/Ritonavir + Famotidine	Atazanavir/Ritonavir + Famotidine	Bristol-Myers Squibb	marketed	HIV protease inhibitor (boosted) + H2-receptor antagonist	HIV protease; CYP3A4 (ritonavir); H2 receptor (famotidine)
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class